Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Insulet Co. (NASDAQ:PODD) has received an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $289.06.

A number of equities research analysts have weighed in on PODD shares. Wells Fargo & Company boosted their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. BTIG Research raised their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James restated an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st.

Insider Buying and Selling at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently modified their holdings of the stock. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in Insulet during the 4th quarter worth $36,000. Itau Unibanco Holding S.A. purchased a new position in Insulet during the 4th quarter worth $42,000. SRS Capital Advisors Inc. grew its stake in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the last quarter.

Insulet Stock Up 0.1 %

Shares of PODD opened at $272.64 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet has a 52 week low of $160.19 and a 52 week high of $289.46. The stock has a market capitalization of $19.15 billion, a price-to-earnings ratio of 47.09, a PEG ratio of 3.62 and a beta of 1.23. The stock has a fifty day moving average of $274.20 and a 200-day moving average of $251.26.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, sell-side analysts anticipate that Insulet will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.